Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics

Sage Therapeutics, Inc. (SAGE)

Today's Latest Price: $148.29 USD

3.95 (2.74%)

Updated Nov 12 10:17am

Add SAGE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 328 in Biotech

See all "A" rated Strong Buy stocks

SAGE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for SAGE is 0 -- better than only 7.17% of US stocks.
  • With a price/sales ratio of 4,607.77, Sage Therapeutics Inc has a higher such ratio than 99.88% of stocks in our set.
  • As for revenue growth, note that SAGE's revenue has grown -98.21% over the past 12 months; that beats the revenue growth of only 0.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sage Therapeutics Inc are VHC, TGTX, CNCE, CBMG, and ZYNE.
  • Visit SAGE's SEC page to see the company's official filings. To visit the company's web site, go to
SAGE Daily Price Range
SAGE 52-Week Price Range

SAGE Stock Price Chart More Charts

SAGE Price/Volume Stats

Current price $148.29
Prev. close $144.34
Day low $136.52
Day high $154.32
50-day MA $147.11
200-day MA $161.44
52-week high $193.56
52-week low $79.88
Volume 122,944
Avg. volume 467,626
Dividend yield N/A
Market Cap 7.66B

Sage Therapeutics, Inc. (SAGE) Company Bio

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.

SAGE Latest News Stream

Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream

Loading social stream, please wait...

View Full SAGE Social Stream

SAGE Price Returns

1-mo 5.51%
3-mo -8.87%
6-mo -12.93%
1-year 22.11%
3-year 187.38%
5-year 322.96%
YTD 54.81%
2018 -41.84%
2017 222.58%
2016 -12.42%
2015 59.29%
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5103 seconds.